Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA Total Debt

Short-term and long-term borrowings combined.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt falls 3.7% from a year ago

Total debt stood at $16.87B at the end of Q2 FY2026, down 3.7% from a year earlier and down 0.2% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Total debt amounted to 42.3% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -3.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$16.87B-0.2% QoQ
Last fiscal yearDec 2025
$17.38B-3.9% YoY
Year agoJun 2025
$17.52B-3.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.7%——
1 year-3.9%——
3-year CAGR-6.9%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
17.38B USD
Year-over-year change
-3.9%
4-year CAGR
-7.2%

Total Debt vs competitors

How TEVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.7% is the 4th highest of 5, against a peer median of +13.5%.
  • Total debt amounts to 42.3% of total assets for TEVA, versus a peer median of 56.4%.
TEVA Competitors
Total Debt for TEVA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹72.6B INR+24.0%+77.9%12.6%
TEVATeva Pharmaceutical Industries LimitedJun 2026$16.87B USD-3.7%-6.9%42.3%
VTRSViatris Inc.Jun 2026$13.63B USD-7.7%-9.0%38.9%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$2.79B USD+8.1%-1.3%73.9%
ALVOAlvotechMar 2026$1.46B USD+18.8%+21.6%102.5%
Peer median (excluding TEVA) —+13.5%+10.2%56.4%

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.17B2.8B3.23B3.3B3.56B
Short-term Investments00000
Net Receivables4.53B3.7B3.41B3.06B3.71B
Inventory3.82B3.83B4.02B3.01B3.18B
Other Current Assets986M559M575M2.18B2.38B
Total Current Assets12.57B12.05B12.49B12.55B13.95B
Property, Plant & Equipment (Net)6.48B6.16B6.15B4.95B4.42B
Goodwill20.04B17.63B17.18B15.15B16B
Intangible Assets7.47B6.27B5.39B4.42B3.78B
Long-term Investments008M00
Tax Assets596M1.46B1.81B1.8B2.19B
Other Non-current Assets515M441M462M462M404.99M
Total Non-current Assets35.09B31.96B30.99B26.77B26.8B
Total Assets47.67B44.01B43.48B39.33B40.75B
Account Payables1.69B1.89B2.6B2.2B2.53B
Short-term Debt1.43B2.11B1.67B1.78B1.82B
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities5.71B5.32B5.2B6.02B8.37B
Total Current Liabilities11.03B11.47B12.25B12.8B13.46B
Long-term Debt21.62B19.1B18.16B16B15.27B
Deferred Tax Liabilities784M548M606M483M296M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.58B3.94B4.02B4.03B3.52B
Total Non-current Liabilities25.4B23.94B23.11B20.81B19.38B
Total Liabilities36.42B35.41B35.35B33.61B32.83B
Common Stock57M57M57M58M58M
Retained Earnings(10.53B)(12.98B)(13.53B)(15.17B)(13.76B)
Accumulated OCI(2.68B)(2.84B)(2.7B)(3.15B)(2.39B)
Other Stockholders Equity001M00
Minority Interest966M794M620M347M4M
Total Equity11.24B8.6B8.13B5.72B7.91B
Total Debt23.46B21.56B20.15B18.08B17.38B
Net Debt21.29B18.76B16.93B14.78B13.83B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.